Sigma Genetics

Executive Summary

Sigma Genetics is a San Diego-based private company developing the Magnetoporator™, a novel platform that employs magnetic fields to generate nanosecond pulsed electric fields (nsPEF) for efficient intracellular delivery of diverse payloads. This technology addresses key limitations in cell engineering, offering a scalable, adjustable, and non-viral approach for applications in drug discovery, cell and gene therapy, and biomanufacturing. Founded in 2016, the company is positioned at the intersection of drug delivery and genetic engineering, with potential to improve the speed and cost of cellular reprogramming. While the company has not disclosed funding or clinical milestones, its platform technology aligns with growing demand for improved delivery methods in the cell and gene therapy sector. The conviction score of 65 reflects the early-stage nature of the company and the lack of publicly available data on revenue or partnerships, balanced by the novelty and scalability of the Magnetoporator platform.

Upcoming Catalysts (preview)

• Q2 2026Series A Funding Round70% success
• Q3 2026Strategic Partnership with a CDMO60% success
• Q3 2026Publication in a Peer-Reviewed Journal80% success